The FLOW trial of semaglutide, the DANCAVAS CV screening trial, non-invasive tests for chest pain, and conflicts of interest on social media are the topics John Mandrola, MD, discusses this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Semaglutide for CKD
Semaglutide Significantly Improves Chronic Kidney Disease
https://www.medscape.com/viewarticle/semaglutide-significantly-improves-chronic-kidney-disease-2024a10009w9
II. CV Screening
Judicious CVD Screening May Work in Men: DANCAVAS
https://www.medscape.com/viewarticle/980153
- DANCAVAS 6-Year Outcomes https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004403
- DANCAVAS Main Trial NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2208681
III. Non-invasive Cardiac Testing in Chest Pain
- Circulation Outcomes Paper https://www.ahajournals.org/doi/abs/10.1161/CIRCOUTCOMES.123.010457
- Scot Heart https://www.nejm.org/doi/full/10.1056/NEJMoa1805971
IV. COI and Social Media
- JAMA letter https://jamanetwork.com/journals/jama/fullarticle/2816900
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
